ArticleOncogene2026
DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Despite aggressive multimodal therapy, including cytotoxic chemotherapy, surgery, and radiation, the prognosis for patients with Ewing sarcoma remains poor, particularly for those with metastatic or relapsed disease. Combining agents that increase DNA replication stress with ATR-CHK1-WEE1 pathway inhibitors, which disrupt the DNA damage response and cell cycle checkpoints, is a promising strategy under clinical investigation in Ewing sarcoma and other cancers. However, the mechanisms by which these drug combinations selectively kill cancer cells under replication stress remain incompletely understood and are often attributed, without strong supporting evidence in many tumor types, to forced mitotic entry. In this study, we show that inhibition of the ATR-CHK1-WEE1 pathway in S-phase-arrested Ewing sarcoma cells triggers rapid apoptosis within 2-4 h, without widespread mitotic entry. This apoptotic response is driven by the activation of cyclin-dependent kinase 1 (CDK1) and is caspase-dependent. We further show that dual targeting of DNA replication and ATR-CHK1-WEE1 signaling in Ewing sarcoma tumors suppresses protein synthesis, and inhibition of protein synthesis prevents cell cycle progression and premature mitotic entry-providing a mechanistic explanation for why aberrant CDK1 activation does not drive mitosis in this context. Moreover, while apoptosis is induced rapidly following drug treatment, the suppression of protein synthesis is prolonged and persists beyond drug removal, suggesting distinct early and late mechanisms of drug-induced toxicity. Collectively, these findings define a unique CDK1- and caspase-dependent apoptotic pathway in response to replication stress and offer new insights into the molecular basis of this therapeutic vulnerability in Ewing sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.